PAREXEL's Pharmaceutical R & D Statistical SourcebookPAREXEL International Corporation, 1996 - Drugs |
Other editions - View all
Common terms and phrases
Analysis ANDA Anti-Infective Average Biologics Biopharmaceuticals Biotech Biotechnology Boston Consulting Group Bristol-Myers Squibb Cancer Cardiovascular CBER CDER chemical entities Clinical Development Clinical Phase Clinical Research Clinical Trials compounds Cost per Patient countries DiMasi diseases Division Drug Approval Drug Development Endocrine Estimated European FDA 1st FDA 2nd FDA Review firms FY94 Cohort Genentech Glaxo Glaxo Wellcome includes IND filing Indication and Phase International Japan Lasagna Lasagna Tufts Center marketing approval Median Merck million Multicountry NCES NCES Approved NDA approval NDA submission Neuropharmacological Neuropharmacological Drug NMES NSAID Number Oncology Oncology and Pulmonary Orphan Drug percent Pfizer pharmaceutical companies Pharmaceutical Industry Pharmaceutical R&D Pharmacoeconomic Phase Phase Phase PhRMA PhRMA Member Pulmonary Drug Products R&D expenditure R&D Spending Report Research and Development Resubmissions Review Phase Selected R&D Notes Self-Originated NCES Source Statistics Study of Drug Success Rates Costs/Complexity Supplements survey therapeutic areas Therapeutic Category Total U.S. Development User Fee Wellcome